“Breast Cancer 3-Day walk kicks off - KARE” plus 4 more |
- Breast Cancer 3-Day walk kicks off - KARE
- Teams fight breast cancer - Daily Telegram
- Cancer center breaks ground: $8.7M expansion to double capacity for ... - Sauk Valley Daily Gazette
- Progesterone Leads To Inflammation, Scientists Find - Science Daily
- The mRNA expression of SETD2 in human breast cancer: correlation with ... - BioMed Central
| Breast Cancer 3-Day walk kicks off - KARE Posted: 21 Aug 2009 09:46 AM PDT The fight against breast cancer took a giant step forward today with the kickoff of the Breast Cancer 3-Day walk. Thousands of women and men will participate again this year, uniting at Southdale Mall in Edina and walking 60 miles through the Twin Cities area to raise funds and awareness for breast cancer. Minnesota residents are urged to show support by attending the Opening and Closing Ceremonies and encouraging walkers at official Cheering Stations along the route. Residents can get more information on these locations at www.The3Day.org Taking place in 15 cities nationwide, the Breast Cancer 3-Day is a series of three-day, 60-mile walks that raise millions of dollars for breast cancer research, education, and community health programs. Breast Cancer 3-Day participants raise a minimum of $2,300 and walk an average of 20 miles a day, educating tens of thousands of people about breast health with every step. As the primary beneficiary of the Breast Cancer 3-Day, Susan G. Komen for the Cure receives 85 percent of net proceeds, and the remaining 15 percent goes to the National Philanthropic Trust Breast Cancer Fund. Walks take place between July - November. For a list of locations and dates, click here. It's not to late for you to get involved. For more information on how to register or donate, click here.
(Copyright 2009 by KARE. All Rights Reserved.)
 This posting includes an audio/video/photo media file: Download Now |
| Teams fight breast cancer - Daily Telegram Posted: 21 Aug 2009 08:06 AM PDT Two breast cancer teams formed this year to participate in the Lake Superior Dragon Boat races on today and Saturday. Team captains are Tammy Miller-Graves of Poplar and Peggy Ryberg of Superior and Peggy Anderson of Duluth is the pledge chairwoman. "The Threesome includes women ages 27-61 and they decided they wanted to celebrate life through humor, laughter, and have just a plain old good time." Anderson said it has not been easy putting together two new teams of breast cancer survivors and supporters. A few members are previous rowers from other teams, and you had to convince the new members that they will not fall into the water. "Only KeyPort can turn over a canoe, and they can't live it down," Anderson said. Find new breast cancer survivors, and supporters from the valley to the hill. Anderson, Ryberg, and Graves-Miller recruited 22 willing participants from each team. Some drop out due to medical reasons; new folks are added. "It's not about your age; our team members are all age levels," Miller-Graves said Ryberg, who is very athletic, feels a good attitude is important toward treatment. These teams won't be wearing pink T-shirts. To quote the National Breast Cancer Coalition, Anderson said, "Less pink, and more research;" pink isn't always pretty. Some participants are looking forward to the races, others are anxious. The team needs to use their strength as paddlers to stay rowing in sync. Some patients who can't row may be in the back seats for medical reasons. Dragon boat racing is a time for cancer survivors, and participants "to embrace life in a group activity that's really has positive energy. Team strength and support is based on camaraderie and is important for everyone, but especially those with mestastic breast cancer. Patients get control over their anger in a cancer diagnosis, as they control the water." Anderson states, "Breast cancer survivors can feel on top of something bigger than themselves by participating in the races. It's a slow transformation into something soothing, rewarding, and very powerful." Anderson said. "We all look beautiful in the water, and there is a tremendous amount of healing in the water."  This posting includes an audio/video/photo media file: Download Now |
| Cancer center breaks ground: $8.7M expansion to double capacity for ... - Sauk Valley Daily Gazette Posted: 21 Aug 2009 09:11 AM PDT By SAM SMITH ssmith@svnmail.com 800-798-4085, ext. 525 DIXON – The Sauk Valley's largest radiological cancer treatment center broke ground Thursday on an $8.7 million expansion and renovation that will more than double its floor space and make available some of the newest technology in cancer treatment. Construction starts today on a new 9,700-square-foot expansion of the Dixon-based Northern Illinois Cancer Treatment Center. By fall 2010, the center will have the new building, plus a complete renovation of its 20-year-old facility. Among the renovation's highlights are a $3 million linear accelerator, which radiation oncologists use to blast tumors with high doses of X-rays. All told, the project will include about $4 million for treatment equipment, and about $4 million for construction, Administrative Director Jon Berens said. Skip Farrell is treasurer of the treatment center's board of directors. The accelerator allows the area to enjoy the advantages of the newest technology in radiation therapy, he said. Board member Jim Sarver called the center "the hub of cancer treatment in the area." Because the center is a nonprofit agency, "Our only reason for being here ... is to give our patients the best treatment possible," Berens said. "These are very exciting times ... It only comes once every 20 years, and it's here today." The renovation will mean fewer people will have to travel to the Quad Cities or Rockford for treatment, Berens said. The center's patients typically live within the region bordered by Princeton, Rochelle, Lanark and Morrison, and it handles about 300 patients a year, Berens said. Most patients are referrals from KSB Hospital and CGH Medical Center. About one-third of all cancer patients receive some type of radiation treatment, which takes an average of 4 weeks, Berens said. Berens hopes to have the expansion complete by May. As soon as that's done, the center will begin renovating the existing building. Highlights of the expansion and renovation The renovation will bring: - A new linear accelerator What a linear accelerator does The Northern Illinois Cancer Treatment Center plans to install a $3 million linear accelerator as the centerpiece of its yearlong expansion and renovation. Here's what an accelerator does: External beam therapy is a method for delivering a beam of high-energy X-rays to a patient's tumor. The beam is generated outside the patient and targets the tumor. These high energy X-rays can deposit their dose to the area of the tumor to destroy cancerous cells. With careful treatment, surrounding tissue remains unharmed. No radioactive sources are placed inside the patient's body. Among other uses, external beam therapy can be used to treat breast, colorectal, head and neck, lung and prostate cancer, as well as brain tumors. Source: www.radiologyinfo.org To donate The Dixon-based Northern Illinois Cancer Treatment Center is a nonprofit agency. To donate to the project, call 815-284-1111. Comments Add CommentsClick here to read the rules for posting commentsThis posting includes an audio/video/photo media file: Download Now |
| Progesterone Leads To Inflammation, Scientists Find - Science Daily Posted: 21 Aug 2009 10:58 AM PDT ScienceDaily (Aug. 21, 2009) — Scientists at Michigan State University have found exposure to the hormone progesterone activates genes that trigger inflammation in the mammary gland. This progesterone-induced inflammation may be a key factor in increasing the risk of breast cancer. Progesterone is a naturally occurring steroid hormone and promotes development of the normal mammary gland. Progesterone previously has been identified as a risk factor for breast cancer, and in a study published in the Journal of Steroid Biochemistry and Molecular Biology, MSU scientists examined the genes activated by progesterone and the effects of their activation in a mouse model system. Exposure to progesterone in normal amounts and in normal circumstances causes inflammation, which promotes breast development. However, exposure to progesterone in menopausal hormone therapy is known to increase breast cancer risk. "Progesterone turns on a wide array of genes involved in several biological processes, including cell adhesion, cell survival and inflammation," said physiology professor Sandra Haslam, co-author of the paper and director of the Breast Cancer and the Environment Research Center at MSU. "All of these processes may be relevant to the development of breast cancer." The study shows progesterone significantly regulates 162 genes in pubertal cells, 104 genes in adult cells and 68 genes at both developmental stages. A number of these genes make small proteins, called chemokines, which control the process of inflammation. Inflammation is a process where white blood cells move into a tissue. One type of white blood cell which moves to the breast during inflammation is a macrophage. Macrophages normally enter growing glands and help them develop, building blood vessels and reshaping growing tissue. "Macrophages also may promote the development of tumors, such as breast cancer, as they make blood vessels to deliver nutrients and can clear the way for tumors to grow," Haslam said. "Long-term exposure to progesterone, such as that which occurs in menopausal hormone therapy, may encourage growth of tumors." Haslam noted that as the link between progesterone and increased breast cancer risk was identified in recent years, women have been taking less hormone therapy after menopause and the rate of breast cancer in older women has gone down. "This study reveals the targets of a specific form of the progesterone receptor, called PRA, in mammary cell development," said microbiology professor Richard Schwartz, a co-author of the paper and associate dean in the College of Natural Science. "The linkages identified provide targets for future work in reducing the influence progesterone has on developing breast cancer. "Understanding the genes that regulate inflammation in the mammary gland will help us to better understand normal breast growth and also may help us devise better treatments for the abnormal growth in cancer." A collaborative team of 10 scientists in MSU's departments of Physiology and Microbiology and Molecular Genetics contributed to the findings. The team's work was published in the July 2009 issue of the journal. The team of faculty is part of MSU's Breast Cancer and the Environment Research Center, one of four centers nationwide funded by the National Institute of Environmental Health Sciences and the National Cancer Institute. The center brings together researchers from MSU's colleges of Natural Science and Human Medicine to study the impact of prenatal-to-adult environmental exposures that may predispose a woman to breast cancer, as well as researchers in the College of Communication Arts and Sciences to study how to best communicate breast cancer health messages to the public.  This posting includes an audio/video/photo media file: Download Now |
| The mRNA expression of SETD2 in human breast cancer: correlation with ... - BioMed Central Posted: 21 Aug 2009 09:32 AM PDT Abstract (provisional)BackgroundSET domain containing protein 2 (SETD2) is a histone methyltransferase that is involved in transcriptional elongation. There is evidence that SETD2 interacts with p53 and selectively regulates its downstream genes. Therefore, it could be implicated in the process of carcinogenesis. Furthermore, this gene is located on the short arm of chromosome 3 and we previously demonstrated that the 3p21.31 region of chromosome 3 was associated with permanent growth arrest of breast cancer cells. This region includes closely related genes namely: MYL3, CCDC12, KIF9, KLHL18 and SETD2. Based on the biological function of these genes, SETD2 is the most likely gene to play a tumour suppressor role and explain our previous findings. Our objective was to determine, using quantitative PCR, whether the mRNA expression levels of SETD2 were consistent with a tumour suppressive function in breast cancer. This is the first study in the literature to examine the direct relationship between SETD2 and breast cancer. MethodsA total of 153 samples were analysed. The levels of transcription of SETD2 were determined using quantitative PCR and normalized against (CK19). Transcript levels within breast cancer specimens were compared to normal background tissues and analyzed against conventional pathological parameters and clinical outcome over a 10 year follow-up period. ResultsThe levels of SETD2 mRNA were significantly lower in malignant samples (p=0.0345) and decreased with increasing tumour stage. SETD2 expression levels were significantly lower in samples from patients who developed metastasis, local recurrence, or died of breast cancer when compared to those who were disease free after more than 10 years of follow up (p=0.041). ConclusionThis study demonstrates a compelling trend for SETD2 transcription levels to be lower in cancerous tissues and in patients who developed progressive disease. These findings are consistent with a possible tumour suppressor function of this gene in breast cancer.  This posting includes an audio/video/photo media file: Download Now |
| You are subscribed to email updates from Add Images to any RSS Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment